Amrize AG heads into its April 30 investor call with a mixed Q1 print already on the table: a sales beat overshadowed by an earnings miss, and a company eager to pivot the conversation toward capital returns.
The headline numbers tell two stories at once. Q1 sales of $2.18B topped the $2.14B estimate — a meaningful beat on the revenue line — but adjusted EPS came in at -$0.16, missing the -$0.13 consensus. The company has historically been a reliable beater on earnings, ranking in the 83rd percentile for EPS surprise, so the miss is a departure from form. Management moved quickly to stabilise sentiment, affirming full-year 2026 sales guidance of $12.29B–$12.52B and announcing the start of a previously-approved $1B share buyback programme.
Shareholders have been receiving other sweeteners alongside the print. On April 14, Amrize declared a special one-time dividend of $0.44 per share, later amended to reflect a 2025 special payout payable May 4. The dividend score ranks in the 71st percentile, reinforcing a capital-return narrative the company has been building since the new CFO, Baris Oran, took the chair on April 1. Combined with the buyback activation, management is signalling confidence in cash generation — operating cashflow is estimated at $2.42B against capex of roughly $900M, leaving meaningful free cashflow headroom.
The lending market shows no sign of stress around the print. Short interest is negligible at just 0.47% of free float, and availability has loosened dramatically — with over 8,000% of estimated short interest available to borrow, there is effectively no constraint on new short positions. Borrowing costs have eased nearly 17% over the past week to 0.50%, a multi-week low. The ORTEX short score has also drifted lower, falling from around 28.8 to 26.6 over the past week, consistent with short sellers backing away rather than building into the event. The stock gained 1% on April 29 and is up roughly 5% over the past month, outperforming peers including CRH (-2.5% on the week) and MLM (roughly flat).
Wells Fargo maintained its Overweight rating on April 15 but trimmed its price target to $65, keeping the analyst community constructive even as the macro backdrop for construction materials has grown more cautious. The EV/EBITDA multiple has eased modestly to around 10.7x, while the P/E has drifted up to 19.6x on 30-day basis — not stretched by sector standards. The April 30 call is therefore less a test of whether Amrize is growing and more a question of whether management can explain the EPS shortfall and convince investors that the buyback pace justifies the premium over sector peers still nursing steeper week-on-week declines.
See the live data behind this article on ORTEX.
Open AMRZ on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
